珠海软银欣创投资8000万元增资优恺泽，科济药业权益稀释至92%
2月27日，科济药业-B（02171）发布公告，宣布与珠海软银欣创达成协议，投资者将以现金对价8000万元认购优恺泽生物医药（上海）有限公司的新增注册资本，约占优恺泽增资后注册资本的8%。此次增资完成后，公司的权益将由100%稀释至92%。优恺泽专注于利用通用型CAR-T细胞疗法治疗血液瘤，获得了相关产品在中国内地的研发、生产与商业化的独家权利。
公告中提到，珠海软银欣创及其最终实益拥有者均为公司的独立第三方，因此本次交易不构成须予公布的交易或关联交易。科济药业致力于成为全球生物制药领域的领导者，为癌症患者提供创新和差异化的细胞疗法，以应对现有CAR-T细胞疗法的挑战。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10